CXChengfei Xu

Chengfei Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chengfei Xu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Baoxia Zhao

    Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, 314001, Jiaxing, China

    2 shared publications
  • Huadong Ni

    Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University

    2 shared publications
  • Jiao Kuang

    Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, 314001, Jiaxing, China

    2 shared publications
  • Ming Yao

    Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University

    2 shared publications
  • Qiuli He

    Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, 314001, Jiaxing, China

    2 shared publications
  • Bing Ma

    Department of Anesthesiology, The Third People's Hospital of Bengbu, 38 Shengli Middle Road, 233000, Bengbu, China

    1 shared publication

Latest Publications

  • Open Access

    Histone modifications and Sp1 promote GPR160 expression in bone cancer pain within rodent models

    by Chengfei Xu, Yahui Wang, Chaobo Ni, Miao Xu, Chengyu Yin, Qiuli He, Bing Ma, Jie Fu, Baoxia Zhao, Liping Chen, et al.

    Bone cancer pain (BCP) affects ~70% of patients in advanced stages, primarily due to bone metastasis, presenting a substantial therapeutic challenge. Here, we profile orphan G protein-coupled receptors in the dorsal root ganglia (DRG) following tumor infiltration, and observe a notable increase in GPR160 expression. Elevated Gpr160 mRNA and protein levels persist from postoperative day 6 for over 18 days in the affected DRG, predominantly in small-diameter C-fiber type neurons specific to the tibia. Targeted interventions, including DRG microinjection of siRNA or AAV delivery, mitigate mechanical allodynia, cold, and heat hyperalgesia induced by the tumor. Tumor infiltration increases DRG neuron excitability in wild-type mice, but not in Gpr160 gene knockout mice. Tumor infiltration results in reduced H3K27me3 and increased H3K27ac modifications, enhanced binding of the transcription activator Sp1 to the Gpr160 gene promoter region, and induction of GPR160 expression. Modulating histone-modifying enzymes effectively alleviated pain behavior. Our study delineates a novel mechanism wherein elevated Sp1 levels facilitate Gpr160 gene transcription in nociceptive DRG neurons during BCP in rodents.


  • Upregulation of LncRNA71132 in the spinal cord regulates hypersensitivity in a rat model of bone cancer pain

    by Huadong Ni, Miao Xu, Jiao Kuang, Chengfei Xu, Qiuli He, Ge Luo, Jie Fu, Jianjun Zhu, Chaobo Ni, Baoxia Zhao, et al.

    Bone cancer pain (BCP) is a pervasive clinical symptom which impairs the quality life. Long noncoding RNAs (lncRNAs) are enriched in the central nervous system and play indispensable roles in numerous biological processes, while its regulatory function in nociceptive information processing remains elusive. Here, we reported that functional modulatory role of ENSRNOT00000071132 (lncRNA71132) in the BCP process and sponging with miR-143 and its downstream GPR85-dependent signaling cascade. Spinal lncRNA71132 was remarkably increased in the rat model of bone cancer pain. The knockdown of spinal lncRNA71132 reverted BCP behaviors and spinal c-Fos neuronal sensitization. Overexpression of spinal lncRNA71132 in naive rat generated pain behaviors, which were accompanied by increased spinal c-Fos neuronal sensitization. Furthermore, it was found that lncRNA71132 participates in the modulation of BCP by inversely regulating the processing of miR-143-5p. In addition, an increase in expression of spinal lncRNA71132 resulted in the decrease in expression of miR-143 under the BCP state. Finally, it was found that miR-143-5p regulates pain behaviors by targeting GPR85. Overexpression of miR-143-5p in the spinal cord reverted the nociceptive behaviors triggered by BCP, accompanied by a decrease in expression of spinal GPR85 protein, but no influence on expression of gpr85 mRNA. The findings of this study indicate that lncRNA71132 works as a miRNA sponge in miR-143-5p–mediated posttranscriptional modulation of GPR85 expression in BCP. Therefore, epigenetic interventions against lncRNA71132 may potentially work as novel treatment avenues in treating nociceptive hypersensitivity triggered by bone cancer.